Pharmacovigilance Reporting: A Doctor’s Obligations Under India’s PvPI Programme

Most Indian doctors have, at some point, seen a patient develop an unexpected or unusual reaction to a medicine — and most of those reactions are never formally reported anywhere. Under-reporting of adverse drug reactions is a well-recognised, global problem, and India’s national system for closing that gap is the Pharmacovigilance Programme of India. This article explains what the programme actually asks of individual doctors, and why reporting matters more than it might seem in the moment.

What PvPI Is

The Pharmacovigilance Programme of India (PvPI) is the Government of India’s national drug safety monitoring system, recast in its current form on April 15, 2011, with the National Coordination Centre based at the Indian Pharmacopoeia Commission (IPC) in Ghaziabad, operating under the Ministry of Health and Family Welfare. PvPI collects, collates, and analyses drug-related adverse events received through a network of ADR Monitoring Centres (AMCs) across the country, and feeds its findings into the Central Drugs Standard Control Organization (CDSCO) for regulatory action — including labelling changes, safety communications, and, where warranted, market withdrawals. PvPI also works in collaboration with the WHO-Uppsala Monitoring Centre, connecting India’s drug safety data to the global pharmacovigilance picture.

Who Can — and Should — Report

Reporting is open to all healthcare professionals — clinicians, dentists, pharmacists, and nurses — as well as non-healthcare professionals, including patients and consumers themselves. There is no formal legal penalty for a doctor who doesn’t report an ADR, but PvPI frames this explicitly as a professional and moral responsibility: as a healthcare professional and citizen, reporting suspected adverse reactions is presented as part of safeguarding public health and improving patient safety, not an optional administrative extra.

What Should Be Reported — the Threshold Is Deliberately Low

A common misconception is that only serious, dramatic, or clearly drug-caused reactions are worth reporting. PvPI’s guidance is the opposite: it explicitly encourages reporting of all types of suspected adverse reactions with all pharmaceutical products, irrespective of whether they are already known or unknown, serious or non-serious, and common or rare. The operative word is “suspected” — a doctor does not need to have confirmed causality before reporting; the entire purpose of the system is to aggregate suspected signals across many reporters so that genuine patterns can be identified that no single doctor would notice from their own practice alone.

What Counts as an ADR for Reporting Purposes

An Adverse Drug Reaction, for PvPI’s purposes, includes any unintended, harmful response to a drug at normal doses. A related but distinct category is an Adverse Event Following Immunization (AEFI) — any untoward medical occurrence following immunisation, which does not necessarily need to have a confirmed causal relationship with the vaccine to be worth reporting; AEFI reporting follows its own specific, parallel process. A Serious Adverse Event (SAE) — any untoward occurrence resulting in death, hospitalisation, or disability — requires expedited reporting given the higher stakes involved.

How the Reporting Process Actually Works

1. A suspected ADR is identified during clinical practice — this can be something a patient reports, something observed during a follow-up visit, or a finding on investigation.
2. The reporting healthcare professional completes the standard ADR reporting form, available through the Indian Pharmacopoeia Commission’s PvPI portal, capturing patient details, the suspected drug, the reaction, and relevant clinical context.
3. The report is submitted either directly to PvPI or through the nearest ADR Monitoring Centre (AMC) — many hospitals and medical colleges host a designated AMC specifically for this purpose.
4. The AMC collects and performs an initial evaluation of the case before forwarding it into the national database.
5. PvPI’s National Coordination Centre aggregates and analyses reports for signal detection — identifying new or emerging safety patterns that individual case reports alone would not reveal.
6. Where a genuine safety signal is confirmed, CDSCO can act on it through regulatory measures, ranging from updated drug labelling to market action.

Why Individual Reports Matter More Than They Seem To

A single ADR report rarely changes anything on its own — and it’s precisely this fact that leads many doctors to conclude reporting isn’t worth the time. But pharmacovigilance systems work through aggregation: a rare but genuine drug safety signal only becomes visible once enough independent reports accumulate across many doctors and patients for a pattern to emerge above background noise. A doctor’s decision not to report doesn’t just withhold one data point — it can be the missing piece that delays recognition of a genuine, serious signal for months or years, particularly for reactions that are individually uncommon but collectively significant.

AMCs: A Resource Many Clinics Don’t Realise Is Nearby

PvPI’s network of ADR Monitoring Centres spans hospitals and medical institutions across India, and many general practitioners and smaller clinics aren’t aware of their nearest one. An AMC can assist with report completion, provide guidance on causality assessment, and serve as a direct submission channel — clinics without an in-house pharmacovigilance process should identify their nearest AMC and build a simple internal referral habit, rather than defaulting to not reporting because the process feels unfamiliar.

How This Connects to Broader Practice

• Informed consent conversations, covered elsewhere in this series, are strengthened by a practice culture that takes drug safety seriously — a clinic that actively participates in ADR reporting is, in a meaningful sense, demonstrating the kind of diligence that also supports defensible clinical documentation.
• Medical negligence risk: while ADR reporting itself is not a negligence-avoidance tool in the direct sense, a documented pattern of monitoring for and responding to adverse reactions supports a picture of attentive, standard-meeting care.
• NABH accreditation: pharmacovigilance and adverse event reporting processes are relevant to the broader patient safety and quality framework NABH evaluates, connecting this to a hospital’s accreditation posture as well as individual clinical practice.

Frequently Asked Questions

Is ADR reporting legally mandatory for doctors in India?

There is no direct legal penalty attached to individual non-reporting; PvPI frames it as a professional and moral responsibility rather than a strictly enforced legal duty, though participation is strongly encouraged as part of good clinical practice.

Do I need to be certain a drug caused the reaction before reporting it?

No. PvPI explicitly asks for suspected reactions to be reported, regardless of confirmed causality — the system is designed to identify patterns across many suspected reports, not to rely on any single doctor confirming causation.

Where can I submit an ADR report?

Reports can be submitted through the Indian Pharmacopoeia Commission’s PvPI portal directly, or through the nearest ADR Monitoring Centre, often based at a local hospital or medical college.

Is vaccine-related adverse event reporting the same as drug ADR reporting?

They are related but distinct — an Adverse Event Following Immunization (AEFI) follows its own specific reporting pathway, separate from the general ADR reporting process, though both feed into national drug and vaccine safety monitoring.

Can patients themselves report an adverse reaction, or does it have to come from a doctor?

Patients and consumers can report directly as well — PvPI accepts reports from both healthcare professionals and non-healthcare professionals, including patients themselves.

Researched Sources

1. Indian Pharmacopoeia Commission — PvPI Frequently Asked Questions
2. Indian Pharmacopoeia Commission — Introduction to PvPI
3. Indian Medical Association — PvPI Initiative Overview
4. PharmaRegulatory.in — PvPI and CDSCO Pharmacovigilance Explained: Ultimate Guide to India’s Drug Safety Framework

Disclaimer

This article is for general informational and educational purposes and reflects the PvPI framework as understood at the time of writing. It is not clinical or regulatory advice; doctors with a suspected adverse drug reaction to report should use the official PvPI reporting channels or contact their nearest ADR Monitoring Centre directly.